Matthew Durdy – VJRegenMed

Addressing remaining barriers to the commercialization of ATMPs

admin_vjr_user — Mon, 08 Nov 2021 18:22:11 +0000

Matthew Durdy, CEO, Cell and Gene Therapy Catapult, London, UK, discusses some of the key remaining barriers to the commercialization of cell and gene therapies. He highlights challenges with patient access to therapies and the way they’re delivered, as well as the importance of enhancing communication with payers in the early stages of product development in order to tackle reimbursement issues. He also notes that increasing manufacturing scale of advanced therapies would lower the cost of goods and facilitate patient access and discusses ongoing work in the UK to better educate academic researchers about the pathway to commercialization. This interview took place at the Advanced Therapies Congress & Expo 2021.

The evolving landscape of autologous and allogeneic therapies

admin_vjr_user — Mon, 08 Nov 2021 18:22:10 +0000

Matthew Durdy, CEO, Cell and Gene Therapy Catapult, London, UK, talks on the evolving landscapes of autologous and allogeneic therapies. Autologous therapies are highly personalized and are able to overcome problems associated with immunogenicity, thus offering the potential for highly effective therapeutics. There is a, however, a growing interest in the development of allogeneic approaches that can be manufactured at a larger scale, although challenges around immunotolerance still need to be addressed. This interview took place at the Advanced Therapies Congress & Expo 2021.

An update on the UK Cell and Gene Therapy Catapult

admin_vjr_user — Wed, 20 Oct 2021 18:03:50 +0000

Matthew Durdy, CEO, Cell and Gene Therapy Catapult, London, UK, gives an update on the Cell and Gene Therapy Catapult (CGTC) and it’s ongoing work in supporting the advanced therapies industry in 2021. With over 400 employees working across five different sites, the CGTC continues to grow rapidly in response to an increasing demand in the industry for new technologies. The introduction of the CGTC’s Braintree facility offers the capacity for the large-scale manufacture of vaccines for COVID-19, as well as other cell and gene therapies in the future. The CGTC also aims to capitalize upon stem cell research and development and contract research organization (CRO) capabilities in Edinburgh going forward. This interview took place at the Advanced Therapies Congress & Expo 2021.

What can the advanced therapies industry learn from the COVID-19 pandemic?

admin_vjr_user — Wed, 20 Oct 2021 18:03:50 +0000

Matthew Durdy, CEO, Cell and Gene Therapy Catapult, London, UK, talks on the impact of the COVID-19 pandemic on the advanced therapies industry. Whilst the pandemic had a negative effect on the progress of clinical trials in the short-term, it raised public awareness of the importance and potential impact of scientific advancement and demonstrated the benefits of the industry working more collaboratively. He also explains how the development of advanced therapeutics could take pressure off healthcare infrastructure through the use of potentially curative treatments following a single administration, thus reducing the number hospital visits compared to standard therapies. This interview took place at the Advanced Therapies Congress & Expo 2021.

The current landscape of advanced therapies in the UK

admin_vjr_user — Wed, 13 Oct 2021 17:11:09 +0000

Matthew Durdy, CEO, Cell and Gene Therapy Catapult, London, UK, provides an overview of the current state of the cell and gene therapies industry in the UK and outlines some of the key areas of ongoing development. He highlights the research and investment in chimeric antigen receptor (CAR) T-cell therapies, gene therapies, RNA-based therapies, as well as non-viral gene delivery technologies. Cell-delivered therapeutics utilizing induced pluripotent stem cell (iPSC) technology to deliver gene therapies to patients are currently under investigation. This interview took place at the Advanced Therapies Congress & Expo 2021.

Building the advanced therapies workforce in the UK

admin_vjr_user — Wed, 14 Jul 2021 11:09:11 +0000

Matthew Durdy, Chief Executive, Cell and Gene Therapy Catapult, London, UK, highlights the importance of building the advanced therapies workforce to support the development and manufacture of therapies as the field continues to grow. He describes some of the approaches being undertaken by the Cell and Gene Therapy Catapult in the UK to enhance training and provide opportunities within the development, manufacturing and adoption phases of advanced therapeutics, such as the Advanced Therapy Skills Training Network, Advanced Therapy Treatment Centers and a range of apprenticeship programs. This interview took place during the Cell & Gene Meeting on the Mediterranean 2021 virtual conference.

The state of investment in cell & gene therapy

admin_vjr_user — Wed, 14 Jul 2021 11:09:10 +0000

Matthew Durdy, Chief Executive, Cell and Gene Therapy Catapult, London, UK, describes the current state of investment in cell and gene therapy sector and outlines key takeaways from a recent panel discussion on this topic at the Cell & Gene Meeting on the Mediterranean 2021 conference. In the panel, it was highlighted that valuation approaches may have been impacted due to the COVID-19 pandemic due to the recognition of the importance of the healthcare industry within national infrastructures, as well as an increase in investment in manufacturing infrastructure. This interview took place during the Cell & Gene Meeting on the Mediterranean 2021 virtual conference.

Tackling manufacturing challenges in advanced therapies

admin_vjr_user — Fri, 30 Apr 2021 10:09:57 +0000

Matthew Durdy, Chief Executive, Cell and Gene Therapy Catapult, London, UK, describes some of the key chemistry, manufacturing and control (CMC) challenges facing the cell and gene therapy sector. He explains how the Cell and Gene Therapy Catapult works closely with companies in the UK to help them with the non-proprietary aspects of large-scale manufacturing by providing infrastructure and expertise on commercialization, manufacturing and regulation. Eight companies are currently operating from and working together in the Catapult’s large-scale GMP manufacturing center, making it the third largest cluster in the world for cell and gene therapy manufacturing. This interview took place during the Cell & Gene Meeting on the Mediterranean 2021 virtual conference.

Harmonizing standards in the advanced therapy industry

admin_vjr_user — Fri, 30 Apr 2021 10:09:56 +0000

Matthew Durdy, Chief Executive, Cell and Gene Therapy Catapult, London, UK, outlines the need for international harmonization and standardized approaches within advanced therapies. By implementing new, consistent standards within the industry, hospitals can more easily adopt or switch to new therapies, which will increase usage of the therapies, lower costs and increase accessibility to patients. Cell and Gene Therapy Catapult has established a network of Advanced Therapy Treatment Centres in the UK and is working with international standards organizations to tackle challenges surrounding standardization in manufacturing, payment and adoption, amongst others. This interview took place during the Cell & Gene Meeting on the Mediterranean 2021 virtual conference.